Literature DB >> 2062379

Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis.

E R Christinck1, M A Luscher, B H Barber, D B Williams.   

Abstract

Antigenic peptides are presented to CD8+T lymphocytes by class I major histocompatibility complex (MHC) molecules. Peptides specifically bind to purified class I molecules in vitro, and to class I molecules on cells at nonphysiological temperatures. We report here the kinetic and equilibrium parameters for the binding of radiolabelled influenza nucleoprotein peptides (NP-Y365-380 and shorter homologues) to the murine H-2Db molecule on intact, viable cells at 37 degrees C. In contrast to earlier reports, we show that peptide binding is rapid and reversible, with dissociation constants ranging from nanomolar to micromolar, suggestive of typical ligand-receptor interactions. Only 10% of cell-surface Db molecules can bind these peptides. To address the relationship between peptide binding and T-cell recognition of the antigen-MHC complex, we determined the minimum number of complexes required to sensitize a target cell for lysis by class I-restricted cytotoxic T-lymphocytes. Our data indicate that EL4 thymoma cells (H-2b) can be sensitized for lysis by cytotoxic T-lymphocytes when as few as 200 class I-peptide complexes (less than 0.08% of surface Db molecules) are present per cell.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2062379     DOI: 10.1038/352067a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  73 in total

1.  HLA-A and HLA-B transcription decrease with ageing in peripheral blood leucocytes.

Authors:  C Le Morvan; M Cogné; M Drouet
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

Authors:  C J Kim; T Prevette; J Cormier; W Overwijk; M Roden; N P Restifo; S A Rosenberg; F M Marincola
Journal:  J Immunother       Date:  1997-07       Impact factor: 4.456

3.  Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens.

Authors:  J Karttunen; S Sanderson; N Shastri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

4.  "Self" to cytotoxic T cells has to be 1,000 or less high affinity nonapeptides per MHC antigen.

Authors:  S Ohno
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

5.  How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level.

Authors:  S Ohno
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

6.  Extensive peptide ligand exchange by surface class I major histocompatibility complex molecules independent of exogenous beta 2-microglobulin.

Authors:  J D Smith; W R Lie; J Gorka; N B Myers; T H Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Design of high-affinity major histocompatibility complex-specific antagonist peptides that inhibit cytotoxic T-lymphocyte activity: implications for control of viral disease.

Authors:  J E Gairin; M B Oldstone
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

8.  Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.

Authors:  L M Mylin; R H Bonneau; J D Lippolis; S S Tevethia
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.

Authors:  A Bertoletti; F V Chisari; A Penna; S Guilhot; L Galati; G Missale; P Fowler; H J Schlicht; A Vitiello; R C Chesnut
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  An in silico model of cytotoxic T-lymphocyte activation in the lymph node following short peptide vaccination.

Authors:  Liam V Brown; Eamonn A Gaffney; Jonathan Wagg; Mark C Coles
Journal:  J R Soc Interface       Date:  2018-03       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.